Literature DB >> 20384422

Cognitive function as an emerging treatment target for marijuana addiction.

Mehmet Sofuoglu1, Dawn E Sugarman, Kathleen M Carroll.   

Abstract

Cannabis is the most widely used illicit substance in the world, and demand for effective treatment is increasing. However, abstinence rates following behavioral therapies have been modest, and there are no effective pharmacotherapies for the treatment of cannabis addiction. We propose a novel research agenda and a potential treatment strategy, based on observations that both acute and chronic exposure to cannabis are associated with dose-related cognitive impairments, most consistently in attention, working memory, verbal learning, and memory functions. These impairments are not completely reversible upon cessation of marijuana use, and moreover may interfere with the treatment of marijuana addiction. Therefore, targeting cognitive impairment associated with chronic marijuana use may be a promising novel strategy for the treatment of marijuana addiction. Preclinical studies suggest that medications enhancing the cholinergic transmission may attenuate cannabis-induced cognitive impairments, but these cognitive enhancing medications have not been examined in controlled human studies. Preliminary evidence from individuals addicted to other drugs suggests that computerized cognitive rehabilitation may also have utility to improve cognitive function in marijuana users. Future clinical studies optimally designed to measure cognitive function as well as drug use behavior would be needed to test the efficacy of these treatments for marijuana addiction. 2010 APA, all rights reserved

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20384422      PMCID: PMC2909584          DOI: 10.1037/a0019295

Source DB:  PubMed          Journal:  Exp Clin Psychopharmacol        ISSN: 1064-1297            Impact factor:   3.157


  150 in total

1.  Neuropsychological performance in long-term cannabis users.

Authors:  H G Pope; A J Gruber; J I Hudson; M A Huestis; D Yurgelun-Todd
Journal:  Arch Gen Psychiatry       Date:  2001-10

2.  The neuropsychological test performance of drug-abusing patients: an examination of latent cognitive abilities and associated risk factors.

Authors:  William Fals-Stewart; Marsha E Bates
Journal:  Exp Clin Psychopharmacol       Date:  2003-02       Impact factor: 3.157

3.  Galantamine may improve attention and speech in schizophrenia.

Authors:  Enrique L M Ochoa; Elizabeth Clark
Journal:  Hum Psychopharmacol       Date:  2006-03       Impact factor: 1.672

4.  Behavioural and biochemical evidence for interactions between Delta 9-tetrahydrocannabinol and nicotine.

Authors:  Emmanuel Valjent; Jennifer M Mitchell; Marie-Jo Besson; Jocelyne Caboche; Rafael Maldonado
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

5.  Computer-assisted cognitive rehabilitation for the treatment of patients with substance use disorders: a randomized clinical trial.

Authors:  William Fals-Stewart; Wendy K K Lam
Journal:  Exp Clin Psychopharmacol       Date:  2010-02       Impact factor: 3.157

6.  Nicotinic facilitation of delta9-tetrahydrocannabinol discrimination involves endogenous anandamide.

Authors:  Marcello Solinas; Maria Scherma; Gianluigi Tanda; Carrie E Wertheim; Walter Fratta; Steven R Goldberg
Journal:  J Pharmacol Exp Ther       Date:  2007-03-09       Impact factor: 4.030

Review 7.  Impulsivity as a determinant and consequence of drug use: a review of underlying processes.

Authors:  Harriet de Wit
Journal:  Addict Biol       Date:  2008-10-09       Impact factor: 4.280

8.  Cannabinoid receptor localization in brain.

Authors:  M Herkenham; A B Lynn; M D Little; M R Johnson; L S Melvin; B R de Costa; K C Rice
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

Review 9.  Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis.

Authors:  David R Janero; Alexandros Makriyannis
Journal:  Expert Opin Emerg Drugs       Date:  2009-03       Impact factor: 4.191

Review 10.  Cholinesterase inhibitors for Alzheimer's disease.

Authors:  J Birks
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25
View more
  23 in total

Review 1.  Cognitive enhancement as a treatment for drug addictions.

Authors:  Mehmet Sofuoglu; Elise E DeVito; Andrew J Waters; Kathleen M Carroll
Journal:  Neuropharmacology       Date:  2012-06-23       Impact factor: 5.250

2.  A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults.

Authors:  Barbara J Mason; Rebecca Crean; Vivian Goodell; John M Light; Susan Quello; Farhad Shadan; Kimberly Buffkins; Mark Kyle; Murali Adusumalli; Adnan Begovic; Santosh Rao
Journal:  Neuropsychopharmacology       Date:  2012-02-29       Impact factor: 7.853

3.  Cognitive performance profiles by latent classes of drug use.

Authors:  P Truman Harrell; Brent Edward E Mancha; Silvia S Martins; Pia M Mauro; Julie H Kuo; Michael Scherer; Karen I Bolla; William W Latimer
Journal:  Am J Addict       Date:  2014-03-15

Review 4.  [Pharmacotherapeutic treatment strategies for smoking cessation].

Authors:  N Vasic; R C Wolf; N Wolf; B J Connemann; Z Sosic-Vasic
Journal:  Nervenarzt       Date:  2011-11       Impact factor: 1.214

Review 5.  Cognitive dysfunction in individuals with cocaine use disorder: Potential moderating factors and pharmacological treatments.

Authors:  James J Mahoney
Journal:  Exp Clin Psychopharmacol       Date:  2018-12-17       Impact factor: 3.157

6.  Effects of chronic, heavy cannabis use on executive functions.

Authors:  Rebecca D Crean; Susan F Tapert; Arpi Minassian; Kai Macdonald; Natania A Crane; Barbara J Mason
Journal:  J Addict Med       Date:  2011-03       Impact factor: 3.702

7.  The safety of modafinil in combination with oral ∆9-tetrahydrocannabinol in humans.

Authors:  Dawn E Sugarman; James Poling; Mehmet Sofuoglu
Journal:  Pharmacol Biochem Behav       Date:  2010-12-21       Impact factor: 3.533

8.  Disturbances of postural sway components in cannabis users.

Authors:  Amanda R Bolbecker; Deborah Apthorp; Ashley Schnakenberg Martin; Behdad Tahayori; Leah Moravec; Karen L Gomez; Brian F O'Donnell; Sharlene D Newman; William P Hetrick
Journal:  Drug Alcohol Depend       Date:  2018-06-21       Impact factor: 4.492

Review 9.  Event-Related Potentials as Biomarkers of Behavior Change Mechanisms in Substance Use Disorder Treatment.

Authors:  Rebecca J Houston; Nicolas J Schlienz
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2017-09-23

10.  Altered subjective reward valuation among drug-deprived heavy marijuana users: Aversion to uncertainty.

Authors:  Kathryn R Hefner; Mark J Starr; John J Curtin
Journal:  J Abnorm Psychol       Date:  2015-11-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.